# Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer

> **NCT01737502** · PHASE1,PHASE2 · COMPLETED · sponsor: **Mayo Clinic** · enrollment: 29 (actual)

## Conditions studied

- Extensive Stage Small Cell Lung Carcinoma
- Lung Adenocarcinoma
- Recurrent Non-Small Cell Lung Carcinoma
- Recurrent Small Cell Lung Carcinoma
- Squamous Cell Lung Carcinoma
- Stage IIIA Non-Small Cell Lung Cancer
- Stage IIIB Non-Small Cell Lung Cancer
- Stage IV Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Auranofin
- **DRUG:** Sirolimus
- **OTHER:** Laboratory Biomarker Analysis
- **OTHER:** Pharmacological Study

## Key facts

- **NCT ID:** NCT01737502
- **Lead sponsor:** Mayo Clinic
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05-14
- **Primary completion:** 2023-04-24
- **Final completion:** 2023-04-24
- **Target enrollment:** 29 (ACTUAL)
- **Last updated:** 2025-09-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01737502

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01737502, "Sirolimus and Auranofin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer or Small Cell Lung Cancer". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01737502. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*